Talk:Strontium ranelate

message: This article makes direct claims that should be supported by references. JFW | T@lk 07:42, 8 July 2007 (UTC)
thread_title:  References 

message: This section should confirm or deny that only the strontium ions have the osteogenic effect.
How soluble is it in water, plasma etc  What % disassociated in the body ?
What effect does the ranelate group have ?  What are the advantages of the ranelate over other soluble strontium salts/compounds ? Rod57 (talk) 15:01, 3 September 2009 (UTC)
replies: text: Found "Strontium ranelate is slightly soluble in purified water (3.7mg/mL at saturation point) and practically insoluble in organic solvents (eg, methanol)." in http://www.medsafe.govt.nz/Profs/datasheet/p/Protossusp.htm which may be the source of the databox values too. Rod57 (talk) 15:10, 3 September 2009 (UTC)
thread_title:  Mode of action 

message: Whoever wrote this part of the article on Strontium Ranelate has made a factual error in stating that this medicine is not available on the NHS in the United Kingdom, it has been available since 2004. The person had written:
Strontium ranelate is registered in more than 70 countries for the treatment of post-menopausal osteoporosis to reduce the risk of vertebral and hip fractures. In the United States, strontium ranelate is not approved by the FDA. In the United Kingdom, the British National Health Service does not use or pay for strontium ranelate as a medicine, because other drugs were determined to be more economical.[1].
The writer used NICE guidelines to substantiate their statement that Strontium Ranelate is not prescribed on the NHS in the UK but this person cannot have read NICE guidance properly. First of all NICE guidance is simply guidance, not NHS law, and secondly the NICE guidance says Strontium Ranleate should only not be first line of treatment for osteoporosis but given when other, cheaper, treatments have failed or are not tolerated. It does not prohibit the prescription of Strontium Ranelate. This 'guidance' is also currently under review and was the subject of a High Court hearing in February 2009. 
I changed the paragraph to:
Strontium ranelate is registered as a prescription drug in more than 70 countries for the treatment of post-menopausal osteoporosis to reduce the risk of vertebral and hip fractures. In the United States, Strontium Ranelate is not approved by the FDA. In the United Kingdom, Strontium Ranelate is prescribed under the National Health Service as a medicine for the treatment of post menopausal osteoporosis.[1].
My link to NHS Choices which describes treatments for osteoporosis with reference to Strontium Ranelate: http://nhs.medguides.medicines.org.uk/nhs/medicine.aspx?name=Strontium%20ranelate&use=Osteoporosis
Paleogirl (talk) 18:09, 20 May 2010 (UTC)
thread_title:  Indication 

message: This statement of fact requires clarification. It is also misleading:
Precaution is advised in patients with phenylketonuria, as strontium ranelate contains phenylalanine
Strontium ranelate in of itself does not "contain" phenylalanine as part of its structure, and to make such a claim even if it did would be inaccurately put. The formulation containing strontium ranelate that is administered may contain phenylalanine (or a chemical that liberates phenylalanine such as aspartame) but this is simply not clear from the original statement.
Upon following the sources list, the formulation is referred to as a "sugar free" preparation, supporting the idea that the formulation contains a source of phenylalanine.  —Preceding unsigned comment added by 77.86.75.231 (talk) 19:27, 25 May 2010 (UTC)
thread_title:  Contraindications 

message: The marketing of the drug will be halted in the months to come, at least in France and E.U. . Toxicity, cardiovascular especially , outweighs the therapeutic benefit. (https://www.vidal.fr/actualites/21036/protelos_ranelate_de_strontium_prochain_arret_de_commercialisation/)90.83.38.167 (talk) 12:40, 15 March 2017 (UTC)
thread_title: withdrawing